INMB
Price
$1.97
Change
-$0.00 (-0.00%)
Updated
Sep 3 closing price
Capitalization
52.11M
55 days until earnings call
OVID
Price
$1.33
Change
+$0.10 (+8.13%)
Updated
Sep 3 closing price
Capitalization
94.22M
69 days until earnings call
Interact to see
Advertisement

INMB vs OVID

Header iconINMB vs OVID Comparison
Open Charts INMB vs OVIDBanner chart's image
INmune Bio
Price$1.97
Change-$0.00 (-0.00%)
Volume$711.74K
Capitalization52.11M
Ovid Therapeutics
Price$1.33
Change+$0.10 (+8.13%)
Volume$1.18M
Capitalization94.22M
INMB vs OVID Comparison Chart in %
Loading...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INMB vs. OVID commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INMB is a Hold and OVID is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (INMB: $1.97 vs. OVID: $1.33)
Brand notoriety: INMB and OVID are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INMB: 23% vs. OVID: 58%
Market capitalization -- INMB: $52.11M vs. OVID: $94.22M
INMB [@Biotechnology] is valued at $52.11M. OVID’s [@Biotechnology] market capitalization is $94.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INMB’s FA Score shows that 0 FA rating(s) are green whileOVID’s FA Score has 1 green FA rating(s).

  • INMB’s FA Score: 0 green, 5 red.
  • OVID’s FA Score: 1 green, 4 red.
According to our system of comparison, OVID is a better buy in the long-term than INMB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INMB’s TA Score shows that 4 TA indicator(s) are bullish while OVID’s TA Score has 5 bullish TA indicator(s).

  • INMB’s TA Score: 4 bullish, 3 bearish.
  • OVID’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, OVID is a better buy in the short-term than INMB.

Price Growth

INMB (@Biotechnology) experienced а -3.67% price change this week, while OVID (@Biotechnology) price change was +5.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.29%. For the same industry, the average monthly price growth was +15.06%, and the average quarterly price growth was +30.89%.

Reported Earning Dates

INMB is expected to report earnings on Oct 29, 2025.

OVID is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+0.29% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
OVID($94.2M) has a higher market cap than INMB($52.1M). OVID YTD gains are higher at: 42.444 vs. INMB (-57.816). INMB (-39.72M) and OVID (-41.01M) have comparable annual earnings (EBITDA) . OVID has more cash in the bank: 38.3M vs. INMB (33.4M). INMB has less debt than OVID: INMB (451K) vs OVID (14.1M). OVID has higher revenues than INMB: OVID (6.65M) vs INMB (50K).
INMBOVIDINMB / OVID
Capitalization52.1M94.2M55%
EBITDA-39.72M-41.01M97%
Gain YTD-57.81642.444-136%
P/E RatioN/AN/A-
Revenue50K6.65M1%
Total Cash33.4M38.3M87%
Total Debt451K14.1M3%
FUNDAMENTALS RATINGS
INMB vs OVID: Fundamental Ratings
INMB
OVID
OUTLOOK RATING
1..100
8528
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
27
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
9734
P/E GROWTH RATING
1..100
10093
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OVID's Valuation (27) in the Pharmaceuticals Major industry is somewhat better than the same rating for INMB (77) in the Biotechnology industry. This means that OVID’s stock grew somewhat faster than INMB’s over the last 12 months.

OVID's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as INMB (100) in the Biotechnology industry. This means that OVID’s stock grew similarly to INMB’s over the last 12 months.

OVID's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as INMB (99) in the Biotechnology industry. This means that OVID’s stock grew similarly to INMB’s over the last 12 months.

OVID's Price Growth Rating (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for INMB (97) in the Biotechnology industry. This means that OVID’s stock grew somewhat faster than INMB’s over the last 12 months.

OVID's P/E Growth Rating (93) in the Pharmaceuticals Major industry is in the same range as INMB (100) in the Biotechnology industry. This means that OVID’s stock grew similarly to INMB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INMBOVID
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
87%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 23 days ago
83%
Bullish Trend 9 days ago
75%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
N/A
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SGPYY58.160.69
+1.20%
Sage Group plc (The)
BRSF0.75N/A
N/A
Brain Scientific, Inc.
FLFG9.00N/A
N/A
Federal Life Group, Inc.
MCSHF2.53N/A
N/A
Metcash Ltd.
IMMFF0.92N/A
N/A
OMNI BRIDGEWAY LTD.

INMB and

Correlation & Price change

A.I.dvisor indicates that over the last year, INMB has been loosely correlated with UNBX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if INMB jumps, then UNBX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INMB
1D Price
Change %
INMB100%
N/A
UNBX - INMB
51%
Loosely correlated
-9.60%
OGEN - INMB
44%
Loosely correlated
+1.90%
GBIO - INMB
36%
Loosely correlated
N/A
PROK - INMB
36%
Loosely correlated
+2.61%
OVID - INMB
35%
Loosely correlated
+8.13%
More

OVID and

Correlation & Price change

A.I.dvisor indicates that over the last year, OVID has been closely correlated with JBIO. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if OVID jumps, then JBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
+8.13%
JBIO - OVID
79%
Closely correlated
-1.64%
ARCT - OVID
46%
Loosely correlated
+2.93%
GBIO - OVID
44%
Loosely correlated
N/A
DNLI - OVID
42%
Loosely correlated
-0.91%
MGNX - OVID
41%
Loosely correlated
+9.77%
More